- AUPH +0.74%
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 64%, as stock drops 9.5% this past week
Yahoo Finance · 6 days ago
Search results
May 7, 2024 · UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference April 15, 2024 • 6:00 am EDT Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
- News & Events
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and...
- Investors & Media
Aurinia Pharmaceuticals Inc. #140, 14315 – 118 Avenue...
- Aurinia in Action
Despite the high incidence of lupus nephritis among people...
- Company Information
Company Contact Aurinia Pharmaceuticals Inc. #140, 14315 –...
- Contact Us
Aurinia Corporate Headquarters #140, 14315 – 118 Avenue...
- Patients
Aurinia is dedicated to showing up for patients and care...
- Our Mission, Vision, Values
Our Mission. Changing the trajectory of autoimmune diseases...
- Stock Data
Stock Data - Press Releases :: Aurinia Pharmaceuticals Inc....
- News & Events
- 5.42Add to watchlist+0.04 (+0.74%)At close: Fri. May 31, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Market closed
- Open5.42High5.66Low5.34
- Mkt Cap775.16MP/E (TTM)N/ADiv & YieldN/A & N/A
- Prev. Close5.3852 Wk. Low4.7152 Wk. High12.43
Top storiesRelated stocks
6 days ago · In the last three years, Aurinia Pharmaceuticals saw its revenue grow by 45% per year, compound. That is faster than most pre-profit companies. In contrast, the share price is down 18% compound ...
2 days ago · View Aurinia Pharmaceuticals Inc AUPH investment & stock information. Get the latest Aurinia Pharmaceuticals Inc AUPH detailed stock quotes, stock data, Real-Time ECN, charts, stats and...
May 24, 2024 · The high in the last 52 weeks of Aurinia Pharmaceuticals stock was 12.61. According to the current price, Aurinia Pharmaceuticals is 41.40% away from the 52-week high. What are analysts...
- Aurinia Pharmaceuticals stock has received a consensus rating of buy. The average rating score is and is based on 17 buy ratings, 0 hold ratings, a...
- The low in the last 52 weeks of Aurinia Pharmaceuticals stock was 4.16. According to the current price, Aurinia Pharmaceuticals is 216.35% away fro...
- The 17 analysts offering price forecasts for Aurinia Pharmaceuticals have a median target of 18.41, with a high estimate of 31.00 and a low estimat...
2 days ago · Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus ...
May 7, 2024 · Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value. Business Wire. Tue, May 7, 2024, 9:00 AM 5 min read. Outlines Concerns Regarding the...
People also ask
Who owns Aurinia Pharmaceuticals Inc?
How high is Aurinia Pharmaceuticals stock?
What is the target price for Aurinia Pharmaceuticals?
May 9, 2024 · ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of two studies at the annual Congress of Clinical Rheumatology (CCR) East 2024 taking place in Destin, FL, May 9-12.
